MERCER ISLAND, Wash., December 7, 2020 – CarepathRx, a leader in comprehensive pharmacy and medication management solutions for health systems, announced it has helped facilitate the administration of bamlanivimab to a COVID patient in collaboration with one of its Texas Health System partners.
Bamlanivimab is an investigational medicine, developed by Eli Lilly, used for the treatment of COVID-19 in non-hospitalized adults and adolescents 12 years of age or older with mild to moderate symptoms and are at high risk for developing severe COVID-19 symptoms or the need for hospitalization. Bamlanivimab has not been approved but has been authorized for emergency use by FDA.
CarepathRx partners with leading health systems to expand their pharmacy operations to provide fully integrated infusion services and therapies in the home. “As the demand for hospital beds rises with an increase in COVID patients, managing hospital capacity by optimizing patient flow, such as transitioning infusion patients to the home for treatment, becomes critical”, said Keith Crawford, Chief Commercial Officer for CarepathRx. “By having the capabilities to effectively and seamlessly move patients into the home for infusion treatment can have a positive impact on hospital bed capacity”.
According to the FDA, Bamlanivimab has been shown in clinical trials to reduce coronavirus-related hospitalizations. “The drug is designed for those who have contracted the virus and are at a higher risk for developing more severe symptoms, Bamlanivimab is only authorized for patients who meet specific criteria”, said Mark Mikhael, Pharm D, Chief Pharmacy Officer at ProHealth Medical. “Being able to offer this treatment in a patient’s home may improve access due to increase patient comfort.”
CarepathRx is transforming pharmacy care delivery for health systems and hospitals, delivering improved patient outcomes that drive clinical and financial results. Through the industry’s most comprehensive, end-to-end hospital pharmacy care delivery model, CarepathRx is turning hospital pharmacy into an active care management strategy and revenue generator while providing support across the patient’s complete healthcare journey. The company takes an enterprise approach, providing a powerful combination of technology, market-leading clinical pharmacy services, and wrap-around services that optimize pharmacy performance across the enterprise for fully integrated pharmacy operations, expanded healthcare services, improved ambulatory access, minimized clinical variation and new health system revenue streams. Today, CarepathRx serves more than 15 health systems and 600 hospitals, with more than 1,500 employees nationwide. For more information about CarepathRx, visit www.carepathrxllc.com.
About ProHealth Medical
ProHealth Medical is owned by CarepathRx and has been helping hospitals improve their financial performance and patient outcomes by establishing home infusion capabilities. By taking a systematic approach, ProHealth has been able to help health systems improve patient access to care and establish a sustainable outpatient infusion book of business that drives hospital brand recognition and increases hospital financial performance. For more information about ProHealth, visit www.prohealthmedical.com.